1. Show article details.

    Hospira President, David J. Endicott, Joins ZELTIQ Aesthetics Board of Directors

    Market Wire – 9:00 AM ET 04/26/2016

    04/26/16 -- ZELTIQ® Aesthetics, Inc. , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced David J. Endicott has joined its Board of Directors. "We are very pleased that David has agreed to join our Board of Directors.

  2. Show article details.

    ZELTIQ Announces Conference Call and Webcast of First Quarter 2016 Financial Results to Be Held on May 10, 2016

    Market Wire – 9:00 AM ET 04/18/2016

    04/18/16 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its first quarter 2016 financial results on Tuesday, May 10, 2016 after the market close.

  3. Show article details.

    Award-Winning CoolSculpting(R) Procedure Now FDA-Cleared to Reduce Fat Around Bra Straps, on the Back and Underneath the Buttocks

    Market Wire – 9:00 AM ET 04/05/2016

    04/05/16 -- ZELTIQ® Aesthetics, Inc. , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced that it received an expanded clearance from the U.S. Food and Drug Administration for the treatment of visible fat bulges of bra fat, back fat and underneath the buttocks.

  4. Show article details.

    ZELTIQ to Present at the 28th Annual ROTH Conference

    Market Wire – 4:01 PM ET 03/09/2016

    03/09/16 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer is scheduled to present at the 28th Annual ROTH Conference in Laguna Niguel, CA. Event: 28th Annual ROTH Conference Date: Monday, March 14, 2016Time: 1:00 pm ...

  5. Show article details.

    ZELTIQ(R) Launches 3-in-1 CoolAdvantage(TM) Applicator for the CoolSculpting(R) System at American Academy of Dermatology Annual Meeting

    Market Wire – 9:00 AM ET 03/03/2016

    03/03/16 --  ZELTIQ® Aesthetics, Inc. , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced the launch of a new family of applicators called CoolAdvantage™ at the American Academy of Dermatology Annual Meeting in Washington, D.C., March 4-8, 2016.

  6. Show article details.

    ZELTIQ Announces Chief Financial Officer Transition

    Market Wire – 4:12 PM ET 02/29/2016

    02/29/16 --  ZELTIQ®, , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, has appointed Taylor C. Harris to the position of Senior Vice President and Chief Financial Officer, effective April 18, 2016.

  7. Show article details.

    ZELTIQ Announces Fourth Quarter and Full Year 2015 Financial Results

    Market Wire – 4:12 PM ET 02/29/2016

    02/29/16 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced financial results for the fourth quarter and full year 2015.

  8. Show article details.

    TherOx Appoints D. Keith Grossman to Its Board of Directors

    Business Wire – 9:00 AM ET 02/22/2016

    TherOx, Inc., a privately held medical device company focused on improved treatment of Acute Myocardial Infarction, announced the appointment of D. Keith Grossman to its board of directors. “Keith is a recognized leader in our industry, and brings a wealth of experience and judgment in guiding innovative device companies through aggressive growth, strategic change, and value creation.

  9. Show article details.

    ZELTIQ Announces Conference Call and Webcast of Fourth Quarter and Full Year 2015 Financial Results to Be Held on February 29, 2016

    Market Wire – 9:00 AM ET 02/12/2016

    02/12/16 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after the market close.

  10. Show article details.

    ZELTIQ to Present at the Leerink Partners 5th Annual Global Healthcare Conference

    Market Wire – 4:01 PM ET 01/28/2016

    01/28/16 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer is scheduled to present at the Leerink Partners 5th Annual Global Healthcare Conference New York City.

  11. Show article details.

    ZELTIQ Added to the S&P SmallCap 600(R) Index

    Market Wire – 4:01 PM ET 01/27/2016

    01/27/16 --  ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that the Company has been selected by S&P Dow Jones Indices to join the S&P SmallCap 600 after the close of trading on January 29, 2016.

  12. Show article details.

    ZELTIQ Announces Executive Leadership Addition and Global Commercial Operations Realignment

    Market Wire – 9:01 AM ET 01/12/2016

    01/12/16 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today additions to its executive leadership team and realignment of its global commercial operations.

  13. Show article details.

    ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2015 Revenue

    Market Wire – 9:00 AM ET 01/12/2016

    01/12/16 -- ZELTIQ®  ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today preliminary unaudited revenue for the fourth quarter and full year 2015.

  14. Show article details.

    ZELTIQ(R) Unveils National CoolSculpting(R) Ad Campaign

    Market Wire – 9:00 AM ET 12/28/2015

    12/28/15 -- ZELTIQ® Aesthetics, Inc. , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced the launch of its national advertising campaign that encourages consumers to Fear No Mirror® with the CoolSculpting® procedure.

  15. Show article details.

    ZELTIQ to Present at the J.P. Morgan 34th Annual Healthcare Conference

    Market Wire – 4:05 PM ET 12/18/2015

    12/18/15 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer is scheduled to present at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, CA. This conference will allow institutional investors to meet ...

  16. Show article details.

    ZELTIQ to Present at the Piper Jaffray 27th Annual Healthcare Conference

    Market Wire – 4:01 PM ET 11/24/2015

    11/24/15 -- ZELTIQ® , a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, is scheduled to present at the Piper Jaffray 27th Annual Healthcare Conference in New York City.

Page:

Today's and Upcoming Events

  • May
    10

    ZLTQ to announce Q1 earnings After Market (Confirmed)

  • May
    10

    ZLTQ Earnings Conference Call at 4:30 PM Listen

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.